Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer
Sintilimab Combined With Long-Course Concurrent Chemoradiotherapy Followed by Capeox Consolidation Chemotherapy vs. Long-Course Concurrent Chemoradiotherapy Followed by Capeox Consolidation Chemotherapy for Total Neoadjuvant Therapy in Patients With Mismatch Repair-Proficient (pMMR) or Microsatellite Stable/Low Microsatellite Instability (MSS/MSI-L) Locally Advanced Rectal Cancer: A Multicenter, Randomized, Double-Blind, Controlled Phase III Study
This is a randomized, double-blind, controlled, Phase III clinical study to evaluate the efficacy and safety of sintilimab combined with long-course concurrent chemoradiotherapy followed by Capeox consolidation chemotherapy, which is planned to enroll 500 subjects with locally advanced rectal cancer.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Yanxi Pu
- 전화번호: +86-18523197816
- 이메일: yanxi.pu@innoventbio.com
연구 장소
-
-
Guangdong
-
Guangzhou, Guangdong, 중국, 510060
- Sun Yat sen University Cancer Center
-
연락하다:
- Ruihua Xu
- 전화번호: +86-20-87343468
- 이메일: xurh2@sysucc.org.cn
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria
- Has signed the written Informed Consent Form and is capable of complying with the visit schedules and relevant procedures specified in the protocol.
- Histopathologically confirmed locally advanced rectal adenocarcinoma, with clinical stage cT3-4NanyM0 or cT1-2N1-2M0 as defined by the AJCC 8th edition, and assessed as amenable to R0 resection after neoadjuvant therapy. MRI demonstrates that the lower edge of the tumor is within 10 cm from the anal verge.
- Tumor pathological tissue testing confirms pMMR, i.e., immunohistochemical staining shows positive expression of all four proteins MLH1, MSH2, MSH6, and PMS2, or tumor tissue-based genetic testing indicates MSI-L or MSS.
- No signs of intestinal obstruction; or intestinal obstruction that has been relieved after proximal colostomy.
- No prior rectal surgery; no prior systemic anti-cancer therapy, or other investigational drug therapy.
- Age ≥18 years, both sexes eligible.
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
- Expected survival of ≥2 years.
- Adequate bone marrow and organ function. Exclusion Criteria
1. Currently participating in another interventional clinical study, except for observational (non-interventional) clinical studies or those in the survival follow-up phase of an interventional study.
2. Plans to receive other anti-tumor therapy during the treatment period of this study.
3. Receipt of any live vaccine within 4 weeks before the first dose of study drug, or plans to receive any live vaccine during the study period.
4. Presence of toxicity from prior therapy that has not recovered to Grade 0 or 1 per NCI CTCAE V6.0 before the first dose of study drug (excluding alopecia, fatigue, pigmentation, and other conditions judged by the investigator to pose no safety risk).
5. Major surgery 6. Receipt of immunosuppressive therapy within 4 weeks before the first dose of study drug, excluding topical corticosteroids administered intranasally, by inhalation, or by other local routes, or physiological doses of systemic corticosteroids , or corticosteroids used to prevent contrast agent allergy.
7. Recurrent rectal cancer; multiple primary colorectal cancers. 8. History of pelvic or abdominal radiotherapy.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: Placebo
Placebo combined with long-course concurrent chemoradiotherapy followed by Capeox consolidation chemotherapy |
130 mg/m²，IV，Q3W 20 ml D1 IV Q3W PTV1 50 Gy/25 times, PTV2 45 Gy/25 times, 5 days a week, for a total of 5 weeks (D1-D35) 825 mg/m ² PO BID ,Days 1-5 QW；1000mg/m ² PO BID ,Days 1-14 Q3W； Radical resection of rectal cancer |
|
실험적: Sintilimab
sintilimab combined with long-course concurrent chemoradiotherapy followed by Capeox consolidation chemotherapy |
130 mg/m²，IV，Q3W PTV1 50 Gy/25 times, PTV2 45 Gy/25 times, 5 days a week, for a total of 5 weeks (D1-D35) 825 mg/m ² PO BID ,Days 1-5 QW；1000mg/m ² PO BID ,Days 1-14 Q3W； Radical resection of rectal cancer 200 mg D1 IV Q3W |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
EFS
기간: throutg treatment completion an average of 5 years
|
EFS refers to the time from randomization to the first occurrence of any of the following events: disease progression precluding surgical treatment, local or distant recurrence, death from any cause, etc. |
throutg treatment completion an average of 5 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
OS
기간: throutg treatment completion an average of 5 years
|
OS is defined as the time from the date of randomization until the date of death from any cause. |
throutg treatment completion an average of 5 years
|
|
CCR
기간: up to 5 years after enrollment
|
CCR defined as the proportion of participants achieving pathological complete response (pCR) or clinical complete response (cCR) |
up to 5 years after enrollment
|
|
R0 resection rate
기간: up to 5 years after enrollment
|
R0 resection rate: Descriptive summary of R0 resection rate |
up to 5 years after enrollment
|
|
EFS3
기간: 3yaers
|
EFS3 defined as the proportion of participants who remain free from any of the following events for 3 years after randomization: disease progression precluding surgery, local or distant recurrence, or death from any cause |
3yaers
|
|
TRG
기간: up to 5 years after enrollment
|
Pathological assessment of tumor regression grading (TRG) after neoadjuvant therapy |
up to 5 years after enrollment
|
|
neoadjuvant therapy completion rate
기간: up to 5 years after enrollment
|
Neoadjuvant therapy completion rate: Descriptive summary of Neoadjuvant therapy completion rate |
up to 5 years after enrollment
|
|
OPR
기간: up to 5 years after enrollment
|
The definition of organ preservation is: no radical total mesorectal excision (TME) performed, and no local regrowth, unless such regrowth can be salvaged by local excision achieving a limited, radical (R0) resection, with no permanent stoma (including a protective stoma that has never been reversed, or a stoma resulting from adverse events and/or poor functional outcome, or a permanent stoma). |
up to 5 years after enrollment
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CIBI308H301
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .